{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:01:51Z","timestamp":1783699311306,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01695-2","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:09:27Z","timestamp":1748329767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer: a single-center retrospective study"],"prefix":"10.1186","volume":"18","author":[{"given":"Yuta","family":"Endo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Takagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Azami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohisa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Nakasato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiya","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"1695_CR1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(18)32552-2","journal-title":"Lancet"},{"key":"1695_CR2","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383. https:\/\/doi.org\/10.1056\/NEJMoa1104390","journal-title":"N Engl J Med"},{"key":"1695_CR3","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1103799","journal-title":"N Engl J Med"},{"key":"1695_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol. 2023;41:609\u201317. https:\/\/doi.org\/10.1200\/JCO.22.01549","journal-title":"J Clin Oncol"},{"key":"1695_CR5","doi-asserted-by":"publisher","first-page":"112908","DOI":"10.1016\/j.ejca.2023.04.024","volume":"189","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, et al. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023;189:112908. https:\/\/doi.org\/10.1016\/j.ejca.2023.04.024","journal-title":"Eur J Cancer"},{"key":"1695_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34:681\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005","journal-title":"Ann Oncol"},{"key":"1695_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","volume":"22","author":"T Shi","year":"2021","unstructured":"Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:439\u201349. https:\/\/doi.org\/10.1016\/S1470-2045(21)00006-1","journal-title":"Lancet Oncol"},{"key":"1695_CR8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","volume":"385","author":"P Harter","year":"2021","unstructured":"Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021;385:2123\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2103294","journal-title":"N Engl J Med"},{"key":"1695_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ygyno.2014.05.029","volume":"134","author":"M Petrillo","year":"2014","unstructured":"Petrillo M, Pedone Anchora L, Tortorella L, Fanfani F, Gallotta V, Pacciani M, et al. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. Gynecol Oncol. 2014;134:257\u201361. https:\/\/doi.org\/10.1016\/j.ygyno.2014.05.029","journal-title":"Gynecol Oncol"},{"key":"1695_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/ijgc-2022-003834","volume":"33","author":"BK Bae","year":"2023","unstructured":"Bae BK, Cho WK, Lee J-W, Kim T-J, Choi CH, Lee Y-Y, et al. Role of salvage radiotherapy for recurrent ovarian cancer. Int J Gynecol Cancer. 2023;33:66\u201373. https:\/\/doi.org\/10.1136\/ijgc-2022-003834","journal-title":"Int J Gynecol Cancer"},{"key":"1695_CR11","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/ijgc-2022-004200","volume":"33","author":"BM Lee","year":"2023","unstructured":"Lee BM, Lee SJ, Kim N, Byun HK, Kim YB. Radiotherapy in recurrent ovarian cancer: updated results of involved-field radiation therapy. Int J Gynecol Cancer. 2023;33:1106\u201311. https:\/\/doi.org\/10.1136\/ijgc-2022-004200","journal-title":"Int J Gynecol Cancer"},{"key":"1695_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3857\/roj.2017.00213","volume":"35","author":"N Choi","year":"2017","unstructured":"Choi N, Chang JH, Kim S, Kim HJ. Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment. Radiat Oncol J. 2017;35:144\u201352. https:\/\/doi.org\/10.3857\/roj.2017.00213","journal-title":"Radiat Oncol J"},{"key":"1695_CR13","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.3802\/jgo.2019.30.e67","volume":"30","author":"N Kim","year":"2019","unstructured":"Kim N, Chang JS, Kim SW, Kim GM, Lee JY, Kim YB. Involved-field radiation therapy for selected cases of recurrent ovarian cancer. J Gynecol Oncol. 2019;30:e67. https:\/\/doi.org\/10.3802\/jgo.2019.30.e67","journal-title":"J Gynecol Oncol"},{"key":"1695_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/ijgc-2019-000247","volume":"29","author":"A Smart","year":"2019","unstructured":"Smart A, Chen Y-H, Cheng T, King M, Lee L. Salvage radiation therapy for localized recurrent ovarian cancer. Int J Gynecol Cancer. 2019;29:916\u201321. https:\/\/doi.org\/10.1136\/ijgc-2019-000247","journal-title":"Int J Gynecol Cancer"},{"key":"1695_CR15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ygyno.2013.04.469","volume":"130","author":"AP Brown","year":"2013","unstructured":"Brown AP, Jhingran A, Klopp AH, Schmeler KM, Ramirez PT, Eifel PJ. Involved-field radiation therapy for locoregionally recurrent ovarian cancer. Gynecol Oncol. 2013;130:300\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.469","journal-title":"Gynecol Oncol"},{"key":"1695_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ygyno.2016.02.005","volume":"141","author":"A Chundury","year":"2016","unstructured":"Chundury A, Apicelli A, DeWees T, Powell M, Mutch D, Thaker P, et al. Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. Gynecol Oncol. 2016;141:134\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2016.02.005","journal-title":"Gynecol Oncol"},{"key":"1695_CR17","doi-asserted-by":"publisher","first-page":"17172","DOI":"10.1038\/s41598-020-74356-7","volume":"10","author":"H Yang","year":"2020","unstructured":"Yang H, Zhang K, Liu Z, Wang T, Shi F, Su J, et al. Clinical analysis of conformal and intensity-modulated radiotherapy in patients with recurrent ovarian cancer. Sci Rep. 2020;10:17172. https:\/\/doi.org\/10.1038\/s41598-020-74356-7","journal-title":"Sci Rep"},{"key":"1695_CR18","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","volume":"25","author":"G Macchia","year":"2020","unstructured":"Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D\u2019Agostino GR, et al. A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups. Oncologist. 2020;25:e311\u201320. https:\/\/doi.org\/10.1634\/theoncologist.2019-0309","journal-title":"Oncologist"},{"key":"1695_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","volume":"101","author":"R Lazzari","year":"2018","unstructured":"Lazzari R, Ronchi S, Gandini S, Surgo A, Volpe S, Piperno G, et al. Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. Int J Radiat Oncol Biol Phys. 2018;101:650\u201360. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.03.058","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1695_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13014-020-01564-w","volume":"15","author":"RO Kowalchuk","year":"2020","unstructured":"Kowalchuk RO, Waters MR, Richardson KM, Spencer K, Larner JM, Irvin WP, et al. Stereotactic body radiation therapy in the treatment of ovarian cancer. Radiat Oncol. 2020;15:108. https:\/\/doi.org\/10.1186\/s13014-020-01564-w","journal-title":"Radiat Oncol"},{"key":"1695_CR21","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1111\/jog.14036","volume":"45","author":"T Kino","year":"2019","unstructured":"Kino T, Ando N, Ogawara Y, Shigeta H. Proton beam therapy for recurrent ovarian carcinoma: a case report. J Obstet Gynaecol Res. 2019;45:1952\u20136. https:\/\/doi.org\/10.1111\/jog.14036","journal-title":"J Obstet Gynaecol Res"},{"key":"1695_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"1695_CR23","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/s0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European organization for research and treatment of Cancer (EORTC) PET study group. Eur J Cancer. 1999;35:1773\u201382. https:\/\/doi.org\/10.1016\/s0959-8049(99)00229-4","journal-title":"Eur J Cancer"},{"key":"1695_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ygyno.2024.07.006","volume":"189","author":"MR Kamrava","year":"2024","unstructured":"Kamrava MR, Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Mirza MR, et al. Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: an ad hoc subgroup analysis of PRIMA\/ENGOT-OV26\/GOG-3012. Gynecol Oncol. 2024;189:68\u201374. https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.006","journal-title":"Gynecol Oncol"},{"key":"1695_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.002","volume":"173","author":"T Gauduchon","year":"2023","unstructured":"Gauduchon T, Kfoury M, Lorusso D, Floquet A, Ventriglia J, Salaun H, et al. PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients. Gynecol Oncol. 2023;173:98\u2013105. https:\/\/doi.org\/10.1016\/j.ygyno.2023.04.002","journal-title":"Gynecol Oncol"},{"key":"1695_CR26","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1136\/ijgc-2022-003543","volume":"32","author":"E Palluzzi","year":"2022","unstructured":"Palluzzi E, Marchetti C, Cappuccio S, Avesani G, Macchia G, Gambacorta MA, et al. Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance. Int J Gynecol Cancer. 2022;32:1164\u201370. https:\/\/doi.org\/10.1136\/ijgc-2022-003543","journal-title":"Int J Gynecol Cancer"},{"key":"1695_CR27","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/ijgc-2024-005361","volume":"34","author":"S Durante","year":"2024","unstructured":"Durante S, Cuccia F, Rigo M, Caminiti G, Mastroleo F, Lazzari R, et al. Stereotactic radiotherapy for managing ovarian cancer oligoprogression under Poly (ADP-ribose) Polymerase inhibitors (PARPi). Int J Gynecol Cancer. 2024;34:1232\u20139. https:\/\/doi.org\/10.1136\/ijgc-2024-005361","journal-title":"Int J Gynecol Cancer"},{"key":"1695_CR28","doi-asserted-by":"publisher","first-page":"101192","DOI":"10.1016\/j.adro.2023.101192","volume":"8","author":"Y Takagawa","year":"2023","unstructured":"Takagawa Y, Suzuki M, Yamaguchi H, Seto I, Azami Y, Machida M, et al. Outcomes and prognostic factors for locally recurrent rectal cancer treated with proton beam therapy. Adv Radiat Oncol. 2023;8:101192. https:\/\/doi.org\/10.1016\/j.adro.2023.101192","journal-title":"Adv Radiat Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01695-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T19:01:50Z","timestamp":1748372510000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01695-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1695"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01695-2","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Southern TOHOKU Research Institute for Neuroscience (No. 565) and was announced on the website of Southern TOHOKU Proton Therapy Center and Southern TOHOKU General Hospital. The research was conducted in accordance with the 1964 Helsinki Declaration. This study was conducted using the opt-out method approved by the ethics committee. Patients or their representatives were provided the opportunity to decline participation through the information disclosed on the institutional website. Individual informed consent was therefore not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}